- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04342962
Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia
Tagraxofusp in Patients With CD123+ or With Blastic Plasmacytoid Dendritic Cell Neoplasm Immunophenotype-like Acute Myeloid Leukemia
Non-randomized, open-label, multicenter phase II Study for the treatment of
- 25 R/R BPDCN-IF (CD123/CD4/CD56 positive) AML patients and
- 25 patients presenting R/R AML CD123+, but negative for either, or both, CD4 and CD56.
Patients will be treated with 12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cicles.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bergamo, Italy
- Recruiting
- Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia
-
Bologna, Italy
- Recruiting
- Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia
-
Contact:
- Antonio Curti
- Phone Number: 328 2262614
- Email: antonio.curti2@unibo.it
-
Brescia, Italy
- Recruiting
- Asst Degli Spedali Civili Di Brescia - Uo Ematologia
-
Contact:
- Chiara Cattaneo
- Phone Number: 3473177157
- Email: chiara.cattaneo@libero.it
-
Genova, Italy
- Recruiting
- Irccs Aou San Martino - Genova - Uo Clinica Ematologica
-
Contact:
- Roberto Massimo Lemoli
- Phone Number: 0103538978
- Email: roberto.lemoli@unige.it
-
Milano, Italy
- Recruiting
- Asst Grande Ospedale Metropolitano Niguarda - Milano - Sc Ematologia
-
Contact:
- Rosa Greco
- Email: rosa.greco@ospedaleniguarda.it
-
Milano, Italy
- Recruiting
- Fondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico - Milano - Ematologia - Padiglione Marcora
-
Perugia, Italy
- Recruiting
- Ao Di Perugia, Ospedale S. Maria Della Misericordia - Ematologia E Trapianto Midollo Osseo
-
Siena, Italy
- Recruiting
- Aou Senese - Uoc Ematologia E Trapianti
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient has evidence of AML in the peripheral blood and/or bone marrow with either BPDCN-IF [CD123/CD4/CD56 (+)] or with AML that is CD123+ but negative for either, or both, CD4 and CD56.
- The patient is ≥18 years old.
- The patient must be refractory to at least one previous line of conventional therapy (either high dose therapy or hypomethylating agents) or relapsed after receiving conventional therapy (a maximum of two previous line of therapy is admitted).
- The patient has an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 0 to 2.
The patient has adequate baseline organ function, including cardiac, renal, and hepatic function:
- Left ventricular ejection fraction (LVEF) ≥institutional lower limit of normal as measured by multigated acquisition (MUGA) scan or 2-dimensional (2-D) echocardiography(ECHO) within 21 days before start of therapy and no clinically significant abnormalities on a 12-lead electrocardiogram (ECG).
- Serum creatinine ≤1.5 mg/dL (133 μmol/L).
- Serum albumin ≥3.2 g/dL (32 g/L) (albumin infusions are not permitted to enable eligibility).
- Bilirubin ≤1.5 mg/dL (26 μmol/L).
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the upper limit of normal (ULN).
- If the patient is a woman of childbearing potential (WOCBP), she must have a negative serum or urine pregnancy test at screeningwithin 1 week before treatment.
- The patient has signed informed consent before initiation of any study-specific procedures or treatment.
- The patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.
- The patient (male and female) agrees to use acceptable contraceptive methods for the duration of time on the study and continue to use acceptable contraceptive methods for 1 week after the last infusion of tagraxofusp.
Exclusion Criteria:
- The patient has a diagnosis of acute promyelocytic leukemia (APL; FAB subtype M3).
- The patient has persistent clinically significant toxicities of Grade≥2 from previous chemotherapy (excluding alopecia, nausea, fatigue, and liver function tests [as mandated in the inclusion criteria]).
- The patient has received treatment with chemotherapy, wide-field radiation, or biologic therapy within 14 days of study entry.
- The patient has received treatment with an investigational agent within 14 days of study entry.
- The patient has previously received treatment with tagraxofusp.
- The patient has an active malignancy and/or cancer history (excluding antecedent MDS) that may confound the assessment of the study endpoints. Patients with a past cancer history (within 2 years of entry) with substantial potential for recurrence and/or ongoing active malignancy will be evaluated on a case by case basis. Patients with the following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, cervical intraepithelial neoplasia, organ-confined prostate cancer with no evidence of progressive disease.
- The patient has clinically significant cardiovascular disease (eg, uncontrolled or any New York Heart Association Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina or stroke within 6 months before study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
- The patient has uncontrolled, clinically significant pulmonary disease (eg, chronic obstructive pulmonary disease, pulmonary hypertension) that, in the opinion of the Investigator, would put the patient at significant risk for pulmonary complications during the study.
- The patient has known active or suspected central nervous system (CNS) leukemia. If suspected, CNS leukemia should be ruled out with relevant imaging and/or examination of cerebrospinal fluid.
- The patient is receiving immunosuppressive therapy - with the exception of low-dose prednisone (≤10 mg/day) - for treatment or prophylaxis of graft-versus-host disease (GVHD). If the patient has been on immunosuppressive treatment or prophylaxis for GVHD, the treatment(s) must have been discontinued at least 14 days before study treatment and there must be no evidence of Grade ≥2 GVHD.
- The patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness/social situations that would limit compliance with study requirements.
- The patient is pregnant or breastfeeding.
- The patient has known positive status for human immunodeficiency virus or active or chronic hepatitis B or hepatitis C (Patients with positive serology for HBV can be enrolled and must receive antiviral prophylaxis - i.e lamivudine or entcavir).
- The patient is oxygen-dependent.
- The patient has any medical condition that, in the opinion of the Investigator, places the patient at an unacceptably high risk for toxicities.
- The patient has AML and requires more than 1 g/day of hydroxyurea (Hydroxyureaispermittedatdoses of ≤1 g/day.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental arm
12 mcg/kg/day of tagraxofusp for 5 days, for at least 4 cycles of therapy; each cycle is 21 days. Patients will receive the study drug until disease progression or in case of toxicity. |
Tagraxofusp is provided as an intravenous (IV) injectable and administered as a 15-minute IV infusion.
Cycle 1 will include a 2-day dosing period for the first 3 enrolled patients (Days 1-2), a 2-day plus an optional 3rd day for patients 4-6 (Days 1-2 + Day 3 if patient meets criteria for continued dosing) and a 3-day dosing period for patients 7 and beyond (Days 1-3).
Cycle 2 and beyond will include a 5-day dosing period for all patients (Days 1-5).
In all cycles and schedules, dose delays up to Day 10 of each cycle will be allowed for resolution of toxicities.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The objective response rate (ORR)
Time Frame: 4 months
|
Evaluate the activity of tagraxofusp, in terms of ORR (PR + CR + CRi), in patients with CD123+ or BlasticPlasmacytoid Dendritic Cell Neoplasm-like phenotype (BPDCN-IF) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML).
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of AEs and SAEs
Time Frame: 28 months
|
Safety analysis according to CTCAE criteria
|
28 months
|
Overall survival (OS)
Time Frame: 24 months
|
Overall survival
|
24 months
|
Event Free Survival (EFS)
Time Frame: 24 months
|
Event Free Survival
|
24 months
|
Disease Free Survival (DFS)
Time Frame: 24 months from response assessment
|
Disease Free Survival
|
24 months from response assessment
|
Cumulative incidence of relapse (CIR)
Time Frame: 24 months from response assessment
|
Cumulative incidence of relapse
|
24 months from response assessment
|
Percentage of patients undergoing allogeneic stem cell transplantation
Time Frame: 12 months
|
in MRD-negative CR
|
12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AML2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingSecondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Adult Acute Myeloid LeukemiaUnited States
Clinical Trials on tagraxofusp
-
Stemline Therapeutics, Inc.CompletedMyelofibrosis | Chronic Myelomonocytic LeukemiaUnited States, Canada
-
Stemline Therapeutics, Inc.TerminatedAcute Myeloid LeukemiaUnited States
-
Karen Ballen, MDRecruitingAcute Myeloid Leukemia | Myelofibrosis | Chronic Myelomonocytic LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBlastic Plasmacytoid Dendritic Cell NeoplasmUnited States
-
Joshua ZeidnerUniversity of North Carolina, Chapel Hill; Stemline Therapeutics, Inc.Not yet recruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...StemlineTherapeutics, Inc.RecruitingAcute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingChronic Myelomonocytic Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Chronic Myelomonocytic Leukemia-1 | Chronic Myelomonocytic Leukemia-2United States
-
Jonsson Comprehensive Cancer CenterStemline Therapeutics, Inc.WithdrawnAcute Myeloid LeukemiaUnited States
-
Stemline Therapeutics, Inc.TerminatedMultiple MyelomaUnited States
-
Therapeutic Advances in Childhood Leukemia ConsortiumRecruitingLymphoma, B-Cell | Hodgkin Lymphoma | Lymphoblastic Lymphoma | Lymphoma, T-Cell | AML | Hematologic Malignancy | MDS | Acute Undifferentiated Leukemia | ALL | Mixed Phenotype Acute Leukemia | BPDCNUnited States, Australia